## ASO Visual Abstract: Awareness and Candidacy for Endocrine Prevention and Risk-Reducing Mastectomy of Unaffected High-Risk Women Referred for Breast Cancer Risk Assessment

Basmah Alhassan, MBBS,  $MSc^{1,2,3}$ , Marianne Bou Rjeily,  $MD^{1,2}$ , Victor Villareal-Corpuz, RN,  $BSc^2$ , Ipshita Prakash, MD,  $MSc^{1,2,4}$ , Mark Basik,  $MD^{1,3}$ , Jean Francois Boileau, MD,  $MSc^1$ , Karyne Martel,  $MD^1$ , Michael Pollak,  $MD^{2,4}$ , William D. Foulkes, MBBS,  $PhD^{2,4,5}$ , and Stephanie M. Wong, MD,  $MPH^{1,2,4,6}$ 


<sup>1</sup>Department of Surgery, McGill University Medical School, Montreal, QC, Canada; <sup>2</sup>Stroll Cancer Prevention Centre, Sir Mortimer B. Davis Jewish General Hospital, Montreal, Canada; <sup>3</sup>Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia; <sup>4</sup>Department of Oncology, McGill University Medical School, Montreal, QC, Canada; <sup>5</sup>Division of Human Genetics, McGill University Medical School, Montreal, QC, Canada; <sup>6</sup>Segal Cancer Centre, Jewish General Hospital, Montreal, QC, Canada

Women referred for high-risk evaluation between 2020 and 2023 completed an initial risk-assessment question-naire that included questions on perceived lifetime risk and consideration of preventive strategies (https://doi.org/10.1245/s10434-023-14566-1). One-way analysis of variance (ANOVA) and chi-square tests were used to compare

differences across different high-risk subgroups. Endocrine prevention is the least considered preventive option for high-risk women despite eligibility of a significant proportion of those presenting with high risk lesions or strong family history.

B. Alhassan et al.

## Awareness and Candidacy for Endocrine Prevention (EP) and Risk Reducing Mastectomy (RRM) in Unaffected High-Risk Women Referred for Breast Cancer Risk Assessment





Completed an intake questionnaire



lesions on breast biopsy (HRL)





38% germline pathogenic variar carriers (GPV)



RRM considered more by GPV carriers (59%) compared to those with HRL (26%) or FH (33%) p=0.001 Overall, 43% eligible for EP including: 92.2% HRL and 36.4% FH



Only 34.5% of those eligible considered EP in the past and 12% had tried EP in the past

Alhassan B. et al. *Ann Surg Oncol*. Visual Abstract for @AnnSurgOncol

ANNALS OF SURGICAL ONCOLOGY